Global and China biopharmaceutical industry report, 2010

In recent years, the biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound annual growth rate of biopharmaceutical industry reached 18.6%, far higher than 8.5% of the global pharmaceutical market, says a new report added to the offerings of Research and Markets. The USA is the most active country in R&D and innovation of biopharmaceutical products, taking the core position in the global biotechnology industry. Now, nearly 60% of biotechnology patents are held by the USA.

At present, there are more than 700 companies in China's biological and bio-chemical pharmaceutical industry, with total sales revenue of about 75.3 billion renminbi ($11.26 billion) in 2009. Growing at a compound annual growth rate (CAGR) of about 30% from 2005 to 2009, China’s biological and bio-chemical pharmaceutical industry had become one of the fastest growing fields in the Chinese pharmaceutical sector. China is still backward in biomedical development compared with European and American countries. Currently, China’s biological and bio-chemical pharmaceutical industry only takes a small proportion in its total pharmaceutical industry, and only contributed 10% to the sales revenue in 2009, so it has ample room for growth.

Blood products dominated by Bayer and Baxter